Eb-Dt-Nk-Uc101
Renal Pelvis/Ureter Urothelial Carcinoma
Beijing BiotechCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
17 Active assets in the Renal Pelvis/Ureter Urothelial Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Nagoya University | Phase 3 | BBB |
Carboplatin Cardiff University | Phase 3 | BBB |
VINBLASTINE University of Southern California | Phase 3 | BBB |
METHOTREXATE University of Southern California | Phase 3 | BBB |
Inno-206 University of Southern California | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Eb-Dt-Nk-Uc101 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →